<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract On 11 March 2020, the coronavirus" exact="disease" post="(COVID-19) was defined by the World Health Organization as"/>
 <result pre="was defined by the World Health Organization as a pandemic." exact="Severe" post="acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human"/>
 <result pre="defined by the World Health Organization as a pandemic. Severe" exact="acute" post="respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus"/>
 <result pre="by the World Health Organization as a pandemic. Severe acute" exact="respiratory" post="syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection"/>
 <result pre="acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus" exact="infection" post="that causes COVID-19, and it first appeared in Wuhan,"/>
 <result pre="such as the 2003 SARS-CoV and the 2012 Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) prompted the identification of compounds that"/>
 <result pre="as the 2003 SARS-CoV and the 2012 Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) prompted the identification of compounds that could"/>
 <result pre="interferons ACE2 TMPRSS2 1. Introduction The pandemic of the coronavirus" exact="disease" post="(COVID-19) has quickly spread to affect almost all countries"/>
 <result pre="countries and territories around the world. The agent causing the" exact="infection" post="was rapidly detected to be a beta coronavirus, first"/>
 <result pre="Committee of Taxonomy of Viruses changed the name to severe" exact="acute" post="respiratory syndrome-2 (SARS-CoV-2), denoting the coronavirus as causing severe"/>
 <result pre="of Taxonomy of Viruses changed the name to severe acute" exact="respiratory" post="syndrome-2 (SARS-CoV-2), denoting the coronavirus as causing severe acute"/>
 <result pre="acute respiratory syndrome-2 (SARS-CoV-2), denoting the coronavirus as causing severe" exact="acute" post="respiratory syndrome-2 [1]. The reported COVID-19 case fatality ranges"/>
 <result pre="respiratory syndrome-2 (SARS-CoV-2), denoting the coronavirus as causing severe acute" exact="respiratory" post="syndrome-2 [1]. The reported COVID-19 case fatality ranges from"/>
 <result pre="the pandemic, the actual numbers of deaths are considerable [2]." exact="Respiratory" post="failure was obviously a major cause of death in"/>
 <result pre="failure was obviously a major cause of death in previous" exact="viral" post="pandemics, including Spanish flu in 1918 and Middle East"/>
 <result pre="viral pandemics, including Spanish flu in 1918 and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012, and this is also"/>
 <result pre="pandemics, including Spanish flu in 1918 and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012, and this is also the"/>
 <result pre="and novel repurposed medications) may shorten the course of the" exact="disease" post="and improve its outcome. However, there is currently no"/>
 <result pre="for these therapies apart from small studies or case series." exact="Severe" post="cases of COVID-19 may need assisted ventilation through various"/>
 <result pre="high number of severe cases (especially elderly) may progress to" exact="acute" post="severe lung injury and/or multiple organ failure due to"/>
 <result pre="targeting of key enzymes of SARS-CoV-2, thus interfering with the" exact="viral" post="cycle inside the host cell by using repurposed antiviral"/>
 <result pre="and monoclonal antibodies. Immunomodulation is particularly needed early in the" exact="disease" post="to boost antiviral immunity, as well as in severe"/>
 <result pre="antiviral immunity, as well as in severe cases where an" exact="uncontrolled" post="immune response may lead to acute lung injury and"/>
 <result pre="severe cases where an uncontrolled immune response may lead to" exact="acute" post="lung injury and other organ damage. This review covers"/>
 <result pre="including the Chinese clinical trial database (http://www.chictr.org.cn/index.aspx). 2. The SARS-CoV-2" exact="Infection" post="2.1. The Structure of the Virus Coronaviruses belong to"/>
 <result pre="their replication (â€œnido-â€� = â€œnestâ€�). They contain the biggest known" exact="viral" post="RNA genomes (27â€&quot;32 kb in length). These viruses are"/>
 <result pre="lymphocytes. The membrane (M) protein has a major role in" exact="viral" post="assembly [10]. The nucleocapsid (N) protein is responsible for"/>
 <result pre="The nucleocapsid (N) protein is responsible for the regulation of" exact="viral" post="RNA synthesisâ€&quot;it interacts with M protein during the budding"/>
 <result pre="cases, especially in the elderly, the symptoms of dyspnea and" exact="hypoxia" post="may develop (with more than 50% lung involvement on"/>
 <result pre="5% of cases, in a late phase of the disease," exact="respiratory" post="failure (due to acute lung injury), shock, and/or multiple"/>
 <result pre="a late phase of the disease, respiratory failure (due to" exact="acute" post="lung injury), shock, and/or multiple organ dysfunction (due to"/>
 <result pre="organ dysfunction (due to the cytokine storm) may develop [13]." exact="Severe" post="cases of COVID-19 that require intensive care unit (ICU)"/>
 <result pre="plasma levels of key inflammatory cytokines including interleukin-2 (IL-2) and" exact="tumor" post="necrosis factor-alpha (TNF-Î±), among many others, thus indicating a"/>
 <result pre="many others, thus indicating a cytokine storm that correlates with" exact="disease" post="severity [13]. Uncontrolled pulmonary inflammation is a major cause"/>
 <result pre="a cytokine storm that correlates with disease severity [13]. Uncontrolled" exact="pulmonary" post="inflammation is a major cause of death in SARS-CoV-2"/>
 <result pre="SARS-CoV-2 infection. More than 80% of patients with COVID-19 have" exact="lymphopenia" post="[13], suggesting the possible pulmonary recruitment of lymphocytes. Another"/>
 <result pre="of patients with COVID-19 have lymphopenia [13], suggesting the possible" exact="pulmonary" post="recruitment of lymphocytes. Another explanation of lymphopenia is immune-related"/>
 <result pre="suggesting the possible pulmonary recruitment of lymphocytes. Another explanation of" exact="lymphopenia" post="is immune-related cell apoptosis or pyroptosis. 3. Antiviral Medications"/>
 <result pre="Several approaches have been suggested to target the current SARS-CoV-2" exact="infection" post="in moderate-to-severe cases in an attempt to control viral"/>
 <result pre="SARS-CoV-2 infection in moderate-to-severe cases in an attempt to control" exact="viral" post="replication; these approaches include (1) the antiviral repurposing of"/>
 <result pre="that leads to the premature or delayed termination of the" exact="viral" post="RNA chains. The drug was first developed for the"/>
 <result pre="The drug was first developed for the treatment of Ebola" exact="infection" post="[15,16]. It was found to be a promising antiviral"/>
 <result pre="prophylactic and therapeutic value of the drug in the MERS-CoV" exact="infection" post="[19]. Another recent in-vitro study reported a half-maximal effective"/>
 <result pre="several drugs tested, only remdesivir (and chloroquine) could inhibit the" exact="virus infection" post="in human cells sensitive to SARS-CoV-2 [20]. Recently, on"/>
 <result pre="drugs tested, only remdesivir (and chloroquine) could inhibit the virus" exact="infection" post="in human cells sensitive to SARS-CoV-2 [20]. Recently, on"/>
 <result pre="enzyme is an aspartic protease that cleaves proteins from precursor" exact="viral" post="polypeptide strands. This applies to structural and functional proteins."/>
 <result pre="functional proteins. The proteases play an important role in the" exact="viral" post="lifecycle, and, if inhibited, immature, non-infectious virions will be"/>
 <result pre="increased with ritonavir. Based on information collected by the Antiretroviral" exact="Pregnancy" post="Registry, the risk of teratogenic effects is not increased"/>
 <result pre="including preterm delivery, stillbirth, low birth weight, and small for" exact="gestational" post="age infants [25]. The combination of lopinavir/ritonavir was effective"/>
 <result pre="of SARS-CoV-2. In contrast, in a study that included 199" exact="adult" post="patients admitted to the hospital with severe COVID-19, lopinavir/ritonavir"/>
 <result pre="with the conventional care regarding the time to clinical improvement," exact="viral" post="load, or mortality [26]. However, the combination of lopinavir"/>
 <result pre="3.1.4. Favipiravir As a guanine analog, favipiravir inhibits the key" exact="viral" post="enzyme RNA-dependent RNA polymerase [30]. Favipiravir has been approved"/>
 <result pre="Favipiravir has been approved for the treatment of influenza viruses" exact="type A" post="and B in a few Asian countries. The use"/>
 <result pre="by a single study to be associated with a better" exact="viral" post="clearance and more frequent radiological improvement compared with lopinavir/ritonavir"/>
 <result pre="guanosine. The drug is mainly used for the treatment of" exact="viral hepatitis" post="C. It has not shown a significant effect as"/>
 <result pre="The drug is mainly used for the treatment of viral" exact="hepatitis C." post="It has not shown a significant effect as a"/>
 <result pre="a corticosteroid, it reduced the 21-day mortality rate due to" exact="acute" post="respiratory distress syndrome (ARDS) in patients with SARS-CoV [33]."/>
 <result pre="corticosteroid, it reduced the 21-day mortality rate due to acute" exact="respiratory" post="distress syndrome (ARDS) in patients with SARS-CoV [33]. Ribavirin"/>
 <result pre="reduced the 21-day mortality rate due to acute respiratory distress" exact="syndrome" post="(ARDS) in patients with SARS-CoV [33]. Ribavirin was also"/>
 <result pre="(in micromolar amounts) used as a model for the new" exact="viral infection" post="of human cells in a study proposed by Klann"/>
 <result pre="micromolar amounts) used as a model for the new viral" exact="infection" post="of human cells in a study proposed by Klann"/>
 <result pre="or arbidol hydrochloride, was developed 25 years ago at the" exact="Russian" post="Research Chemical and Pharmaceutical Institute. Umifenovir is approved for"/>
 <result pre="is approved for the prophylaxis and treatment of human influenza" exact="type A" post="and type B infections, as well as post-influenza complications"/>
 <result pre="the prophylaxis and treatment of human influenza type A and" exact="type B" post="infections, as well as post-influenza complications (only in a"/>
 <result pre="Overall, umifenovir has a broad variety of antiviral activity against" exact="hepatitis" post="B virus, respiratory syncytial virus, adenovirus, parainfluenza virus, avian"/>
 <result pre="a broad variety of antiviral activity against hepatitis B virus," exact="respiratory" post="syncytial virus, adenovirus, parainfluenza virus, avian coronavirus, coxsackie B3"/>
 <result pre="and arthropod-borne flaviviruses including Zika virus, West Nile virus, and" exact="tick-borne encephalitis," post="thus indicating broad-spectrum antiviral activities [38]. A current trial"/>
 <result pre="for two weeks (NCT04254874). 3.1.7. Oseltamivir Oseltamivir is a competitive" exact="viral" post="neuraminidase enzyme inhibitor. The enzyme inhibition interferes with the"/>
 <result pre="progeny influenza virus from the infected host cells; thus, new" exact="viral" post="cycles are inhibited. After the replication of the virus,"/>
 <result pre="virion release [39]. Oseltamivir is active against a variety of" exact="respiratory" post="viruses, including influenza A and influenza B. Oseltamivir can"/>
 <result pre="The influenza neuraminidase enzyme is highly conserved, being common to" exact="type A" post="H1N1, type A H2N2, type A H3N2, type A"/>
 <result pre="enzyme is highly conserved, being common to type A H1N1," exact="type A" post="H2N2, type A H3N2, type A H5N1, and type"/>
 <result pre="conserved, being common to type A H1N1, type A H2N2," exact="type A" post="H3N2, type A H5N1, and type B influenza viruses"/>
 <result pre="to type A H1N1, type A H2N2, type A H3N2," exact="type A" post="H5N1, and type B influenza viruses [40]. Interestingly, oseltamivir"/>
 <result pre="type A H2N2, type A H3N2, type A H5N1, and" exact="type B" post="influenza viruses [40]. Interestingly, oseltamivir is also active against"/>
 <result pre="3 (NLRP3) and inflammasome, thus inducing cell pyroptosis in SARS-CoV-2" exact="infection" post="[46]. Tranilast is an antagonist of NLRP3 that inhibits"/>
 <result pre="tryptophan analog used to treat allergic conditions, including bronchial asthma," exact="atypical" post="dermatitis, and allergic conjunctivitis [47]. Interestingly, the drug is"/>
 <result pre="to treat allergic conditions, including bronchial asthma, atypical dermatitis, and" exact="allergic conjunctivitis" post="[47]. Interestingly, the drug is registered for a Chinese"/>
 <result pre="treat allergic conditions, including bronchial asthma, atypical dermatitis, and allergic" exact="conjunctivitis" post="[47]. Interestingly, the drug is registered for a Chinese"/>
 <result pre="Chinese clinical trial in the treatment of COVID-19 (ChiCTR2000030002). The" exact="primary" post="inflammatory responses are usually mild and can be overcome"/>
 <result pre="and can be overcome by most patients. It is the" exact="secondary" post="inflammatory response that is frequently florid and fatal. Though"/>
 <result pre="clearance of the virus (as evidenced by the decrease in" exact="viral" post="load), anti-spike protein-neutralizing antibodies (anti-S-IgG) in SARS-CoV infection have"/>
 <result pre="decrease in viral load), anti-spike protein-neutralizing antibodies (anti-S-IgG) in SARS-CoV" exact="infection" post="have been found to cause severe lung injury by"/>
 <result pre="Similarly, the vaccine for SARS-CoV has been found to induce" exact="pulmonary" post="injury in multiple animal models [49,50]. In COVID-19 patients,"/>
 <result pre="the accumulation of the proinflammatory monocyte/macrophage and the production of" exact="monocyte" post="chemoattractant protein-1 (MCP-1) and IL-8 in the lungs. The"/>
 <result pre="(Figure 2) [48]. A previously described phenomenonâ€&quot;the antibody-dependent enhancement of" exact="viral infection" post="(ADE)â€&quot;may be a plausible explanation. The process of ADE"/>
 <result pre="2) [48]. A previously described phenomenonâ€&quot;the antibody-dependent enhancement of viral" exact="infection" post="(ADE)â€&quot;may be a plausible explanation. The process of ADE"/>
 <result pre="explanation. The process of ADE enhances the cellular uptake of" exact="infectious" post="virus-antibody complexes after their interaction with FcR or other"/>
 <result pre="or other receptors, leading to the exacerbation of target cell" exact="infection" post="[52]. FcR can be blocked by IVIG, thus suppressing"/>
 <result pre="severe cases of COVID-19. The role of IVIG in severe" exact="infections" post="and sepsis is still controversial and warrants further well-designed"/>
 <result pre="one of the first cytokines released in the context of" exact="viral infection." post="The IFNAR receptors recognize it on the plasma membrane"/>
 <result pre="nucleus to activate interferon-stimulated genes (ISG). The ISGs interfere with" exact="viral" post="replication and spread by several mechanisms such as the"/>
 <result pre="also comprise antiviral proteins that specifically inhibit steps of the" exact="viral" post="cycle [57]. Previously, interferon treatment showed inconclusive activity against"/>
 <result pre="activity against SARS-CoV and MERS-CoV. IFNÎ²1 up-regulates CD73 in the" exact="pulmonary" post="endothelium, leading to adenosine secretion. Adenosine is an anti-inflammatory"/>
 <result pre="molecule that supports the endothelial barrier. Thus, interferon treatment reduces" exact="vascular" post="leakage in ARDS, [58]. Unfortunately, such an anti-inflammatory effect"/>
 <result pre="One assumption of COVID-19-associated severe lung injury is that the" exact="virus infection" post="provokes an exaggerated IFN-I-mediated response against the virus, leading"/>
 <result pre="assumption of COVID-19-associated severe lung injury is that the virus" exact="infection" post="provokes an exaggerated IFN-I-mediated response against the virus, leading"/>
 <result pre="be administered to patients in the early phase of the" exact="disease" post="[60]. However, it is plausible that an anti-interferon agent"/>
 <result pre="Baricitinib is reported to be effective in the treatment of" exact="rheumatoid arthritis" post="in several clinical trials [65], with excellent results in"/>
 <result pre="is reported to be effective in the treatment of rheumatoid" exact="arthritis" post="in several clinical trials [65], with excellent results in"/>
 <result pre="by different cytokines in the blood, and it causes a" exact="transient" post="alteration in neutrophil and lymphocyte counts [66,67,68,69]. Receptor-mediated endocytosis"/>
 <result pre="a cell surface protein expressed by cells in the kidney," exact="blood vessels," post="heart, and, most importantly, lung AT2 alveolar epithelial cells,"/>
 <result pre="kidney, blood vessels, heart, and, most importantly, lung AT2 alveolar" exact="epithelial" post="cells, is the receptor used by SARS-CoV-2 to infect"/>
 <result pre="were used together to identify drugs that may halt the" exact="viral infection" post="process. Baricitinib was expected to have a high binding"/>
 <result pre="used together to identify drugs that may halt the viral" exact="infection" post="process. Baricitinib was expected to have a high binding"/>
 <result pre="baricitinib is suggested to be trialed on patients with SARS-CoV-2" exact="acute" post="respiratory disease in order to reduce the viral entry"/>
 <result pre="is suggested to be trialed on patients with SARS-CoV-2 acute" exact="respiratory" post="disease in order to reduce the viral entry and"/>
 <result pre="suggested to be trialed on patients with SARS-CoV-2 acute respiratory" exact="disease" post="in order to reduce the viral entry and the"/>
 <result pre="with SARS-CoV-2 acute respiratory disease in order to reduce the" exact="viral" post="entry and the associated inflammation (NCT04321993). A great chance"/>
 <result pre="as lopinavir, ritonavir, and remdesivir, since this combination would decrease" exact="viral" post="infectivity, viral replication, and the exaggerated host inflammatory response."/>
 <result pre="ritonavir, and remdesivir, since this combination would decrease viral infectivity," exact="viral" post="replication, and the exaggerated host inflammatory response. On the"/>
 <result pre="baricitinib is associated with an increased risk of developing severe" exact="infections" post="due to opportunistic pathogens, especially if it is taken"/>
 <result pre="it is taken concomitantly with immunosuppressants such as corticosteroids [74]." exact="Tuberculosis" post="was identified in patients receiving baricitinib, and patients should"/>
 <result pre="should be tested prior to and during therapy for latent" exact="tuberculosis" post="infection. In addition, thrombosis, including deep venous thrombosis and"/>
 <result pre="during therapy for latent tuberculosis infection. In addition, thrombosis, including" exact="deep venous thrombosis" post="and pulmonary embolism, has been documented more than placebo"/>
 <result pre="for latent tuberculosis infection. In addition, thrombosis, including deep venous" exact="thrombosis" post="and pulmonary embolism, has been documented more than placebo"/>
 <result pre="tuberculosis infection. In addition, thrombosis, including deep venous thrombosis and" exact="pulmonary embolism," post="has been documented more than placebo in patients treated"/>
 <result pre="JAK1 and JAK2 inhibitor. It was the first drug for" exact="myelofibrosis" post="to be approved by the FDA in November 2011"/>
 <result pre="endocytosis greatly exceeds the currently tolerated therapeutic dose [73]. Therefore," exact="viral" post="infectivity at therapeutic doses is unlikely to decrease, but"/>
 <result pre="to its ligand, PD-L1, thus inhibiting the immune escape of" exact="tumor" post="cells [76]. Recently, in China, the drug has received"/>
 <result pre="sepsis patients, PD-1 and PD-L1 are known to be the" exact="primary" post="mediators in T cell depletion [79]. Animal models have"/>
 <result pre="determine the effectiveness of PD-1 inhibitors in 2019 novel coronavirus" exact="infection" post="in patients with serious lymphocytopenia-associated pneumonia. On the other"/>
 <result pre="formation. In the United States, eculizumab is approved for treating" exact="paroxysmal nocturnal hemoglobinuria" post="and atypical hemolytic uremic syndrome [82,83]. The literature has"/>
 <result pre="In the United States, eculizumab is approved for treating paroxysmal" exact="nocturnal" post="hemoglobinuria and atypical hemolytic uremic syndrome [82,83]. The literature"/>
 <result pre="the United States, eculizumab is approved for treating paroxysmal nocturnal" exact="hemoglobinuria" post="and atypical hemolytic uremic syndrome [82,83]. The literature has"/>
 <result pre="States, eculizumab is approved for treating paroxysmal nocturnal hemoglobinuria and" exact="atypical" post="hemolytic uremic syndrome [82,83]. The literature has identified the"/>
 <result pre="eculizumab is approved for treating paroxysmal nocturnal hemoglobinuria and atypical" exact="hemolytic uremic syndrome" post="[82,83]. The literature has identified the complement system as"/>
 <result pre="approved for treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic" exact="syndrome" post="[82,83]. The literature has identified the complement system as"/>
 <result pre="as an essential host mediator for both SARS-CoV- and MERS-CoV-induced" exact="disease" post="and has suggested that complement activation controls the systemic"/>
 <result pre="MERS-CoV-induced disease and has suggested that complement activation controls the" exact="systemic" post="pro-inflammatory response against the viral infection [84,85]. Accordingly, eculizumab"/>
 <result pre="that complement activation controls the systemic pro-inflammatory response against the" exact="viral infection" post="[84,85]. Accordingly, eculizumab is expected to stop immune-mediated death"/>
 <result pre="complement activation controls the systemic pro-inflammatory response against the viral" exact="infection" post="[84,85]. Accordingly, eculizumab is expected to stop immune-mediated death"/>
 <result pre="clinical trials for its effectiveness in patients with confirmed COVID-19" exact="infection" post="who are in ICU due to ARDS (NCT04288713). 4.5."/>
 <result pre="was found to speed up the recovery of patients with" exact="pneumonia" post="associated with COVID-19 infection with a favorable safety profile"/>
 <result pre="up the recovery of patients with pneumonia associated with COVID-19" exact="infection" post="with a favorable safety profile [87]. The findings of"/>
 <result pre="immune response and is associated with the pathogenesis of many" exact="autoimmune diseases" post="[88]. IL-6 is produced by different cells, including T-cells"/>
 <result pre="approved for the treatment of serious or life-threatening cytokine release" exact="syndrome" post="(CRS). The FDA has approved a randomized, double-blind, placebo-controlled"/>
 <result pre="the standard of care in hospitalized patients with severe COVID-19" exact="pneumonia" post="[89]. The seventh edition of the Chinese Clinical Guidance"/>
 <result pre="The seventh edition of the Chinese Clinical Guidance for COVID-19" exact="Pneumonia" post="Diagnosis and Treatment published by China National Health Commission"/>
 <result pre="positive outcomes from the use of tocilizumab to control dangerous" exact="lung inflammation" post="in 21 patients with severe COVID-19 in China [91]."/>
 <result pre="been reported in patients treated with tocilizumab, including cases of" exact="acute" post="liver failure that required a transplant [92]. Patients should"/>
 <result pre="reported in patients treated with tocilizumab, including cases of acute" exact="liver failure" post="that required a transplant [92]. Patients should be closely"/>
 <result pre="closely monitored for the emergence of signs and symptoms of" exact="infection" post="during and after treatment with tocilizumab, including the potential"/>
 <result pre="and after treatment with tocilizumab, including the potential development of" exact="tuberculosis" post="in patients who have tested negative for latent tuberculosis"/>
 <result pre="of tuberculosis in patients who have tested negative for latent" exact="tuberculosis" post="infection before starting therapy. Many patients who acquired these"/>
 <result pre="tuberculosis in patients who have tested negative for latent tuberculosis" exact="infection" post="before starting therapy. Many patients who acquired these infections"/>
 <result pre="for latent tuberculosis infection before starting therapy. Many patients who" exact="acquired" post="these infections were taking concomitant immunosuppressants, such as methotrexate"/>
 <result pre="tuberculosis infection before starting therapy. Many patients who acquired these" exact="infections" post="were taking concomitant immunosuppressants, such as methotrexate or corticosteroids,"/>
 <result pre="sarilumab-treated patients are at an elevated risk of developing severe" exact="opportunistic infections" post="that may result in hospitalization or death [95]. 4.8."/>
 <result pre="patients are at an elevated risk of developing severe opportunistic" exact="infections" post="that may result in hospitalization or death [95]. 4.8."/>
 <result pre="anti-tumor therapy for 16 years. It binds to and neutralizes" exact="vascular" post="endothelial growth factor (VEGF), preventing its interaction with endothelial"/>
 <result pre="interaction with endothelial receptors, Flt-1 and KDR. The suppression of" exact="vascular" post="permeability in patients with severe/critical COVID-19 is expected to"/>
 <result pre="permeability in patients with severe/critical COVID-19 is expected to reduce" exact="pulmonary" post="edema. The autopsies of patients who died from COVID-19"/>
 <result pre="died from COVID-19 have shown the significant exudation of the" exact="pulmonary" post="mucus, more evident than infection with SARS [96]. Pulmonary"/>
 <result pre="the significant exudation of the pulmonary mucus, more evident than" exact="infection" post="with SARS [96]. Pulmonary CT scanning and pathological observation"/>
 <result pre="the pulmonary mucus, more evident than infection with SARS [96]." exact="Pulmonary" post="CT scanning and pathological observation have recognized inflammatory exudation"/>
 <result pre="controlled clinical trial [98]. Bevacizumab has been reported by the" exact="American" post="Heart Association to be an agent that may either"/>
 <result pre="clinical trial [98]. Bevacizumab has been reported by the American" exact="Heart" post="Association to be an agent that may either cause"/>
 <result pre="dysfunction Moreover, bevacizumab has been reported to cause and/or worsen" exact="hypertension" post="[98]. Thus, blood pressure monitoring during bevacizumab treatment and"/>
 <result pre="of lung injury. Fingolimod is mainly contra-indicated in patients with" exact="myocardial infarction" post="(within six months), unstable angina, stroke, heart failure, and"/>
 <result pre="mainly contra-indicated in patients with myocardial infarction (within six months)," exact="unstable angina," post="stroke, heart failure, and heart block. Prolonged QT interval"/>
 <result pre="patients with myocardial infarction (within six months), unstable angina, stroke," exact="heart" post="failure, and heart block. Prolonged QT interval above 500"/>
 <result pre="myocardial infarction (within six months), unstable angina, stroke, heart failure," exact="and heart" post="block. Prolonged QT interval above 500 m/s is another"/>
 <result pre="infarction (within six months), unstable angina, stroke, heart failure, and" exact="heart" post="block. Prolonged QT interval above 500 m/s is another"/>
 <result pre="m/s is another important contra-indication, given the high incidence of" exact="myocarditis" post="as a complication of severe COVID-19. Patients with diabetes"/>
 <result pre="of myocarditis as a complication of severe COVID-19. Patients with" exact="diabetes" post="may get macular edema upon fingolimod treatment [100]. A"/>
 <result pre="for three consecutive days in the treatment of severe COVID-19" exact="infection" post="(NCT04280588). 5. Other Anti-Infective Agents Repurposed to Treat COVID-19"/>
 <result pre="(HCQ) are antimalarial drugs that are also prescribed in treating" exact="autoimmune diseases" post="[101]. According to the literature, both chloroquine and hydroxychloroquine"/>
 <result pre="activity against several viruses. CQ, through the inhibition of specific" exact="viral" post="replication steps, restricts HIV. [102], influenza virus [103], dengue"/>
 <result pre="[103], dengue virus (DENV), [104], West Nile virus (WNV) infection," exact="Japanese encephalitis" post="virus (JEV), and Zika virus infection [105]. Those specific"/>
 <result pre="dengue virus (DENV), [104], West Nile virus (WNV) infection, Japanese" exact="encephalitis" post="virus (JEV), and Zika virus infection [105]. Those specific"/>
 <result pre="Nile virus (WNV) infection, Japanese encephalitis virus (JEV), and Zika" exact="virus infection" post="[105]. Those specific viral replication steps depend on the"/>
 <result pre="virus (WNV) infection, Japanese encephalitis virus (JEV), and Zika virus" exact="infection" post="[105]. Those specific viral replication steps depend on the"/>
 <result pre="encephalitis virus (JEV), and Zika virus infection [105]. Those specific" exact="viral" post="replication steps depend on the pH. The investigation of"/>
 <result pre="HCQ have been used for the treatment and prophylaxis of" exact="malaria" post="and rheumatic diseases for more than 50 years. Second,"/>
 <result pre="been used for the treatment and prophylaxis of malaria and" exact="rheumatic" post="diseases for more than 50 years. Second, both drugs"/>
 <result pre="endosome/lysosome trafficking. Another potential mechanism is the intervention with the" exact="viral" post="protein maturation during virion maturation [107]. CQ has been"/>
 <result pre="Given that, and because of the previously described cases of" exact="myocarditis" post="in COVID-19, CQ and HCQ should be cautiously prescribed"/>
 <result pre="cautiously prescribed under close clinical supervision by specialists. Patients with" exact="myocarditis" post="are expected to be more susceptible to cardiac adverse"/>
 <result pre="should be monitored closely for adverse effects during use. The" exact="American" post="College of Cardiology has recommended QTc monitoring parameters in"/>
 <result pre="HCQ was apparently associated with a more rapid decline in" exact="viral" post="RNA; however, the control groups for the study were"/>
 <result pre="in patients with more severe illness did not suggest rapid" exact="viral" post="RNA clearance with the combination [112]. 5.2. Ivermectin Ivermectin"/>
 <result pre="in the oral tablet dosage form, is used to treat" exact="infections" post="of parasites, including the intestinal tract, skin, and eyes"/>
 <result pre="Ivermectin in sub-nanomolar range EC50 inhibits the replication of the" exact="yellow fever" post="virus [113]. Ivermectin is also able to inhibit other"/>
 <result pre="is also able to inhibit other flavivirus replication, including: dengue," exact="tick-borne encephalitis," post="and Japanese encephalitis viruses. One of the mechanisms involved"/>
 <result pre="to inhibit other flavivirus replication, including: dengue, tick-borne encephalitis, and" exact="Japanese encephalitis" post="viruses. One of the mechanisms involved in this inhibition"/>
 <result pre="inhibit other flavivirus replication, including: dengue, tick-borne encephalitis, and Japanese" exact="encephalitis" post="viruses. One of the mechanisms involved in this inhibition"/>
 <result pre="RNA viruses. Thus, ivermectin blocks the nuclear trafficking of RNA" exact="viral" post="proteins. Ivermectin has been shown to have potent antiviral"/>
 <result pre="treated with ivermectin [117]. Ivermectin administration resulted in a successful" exact="viral" post="loss by 48 h with no further reduction in"/>
 <result pre="viral loss by 48 h with no further reduction in" exact="viral" post="RNA at 72 h. The authors hypothesized that ivermectin"/>
 <result pre="exerts its antiviral activity by inhibiting the nuclear import of" exact="viral" post="proteins that is mediated by importinÎ±/Î²1â€&quot;the same mechanism discussed"/>
 <result pre="hand, clarithromycin and azithromycin have shown higher effectivity towards rhinovirus," exact="respiratory" post="syncytial virus, and influenza virus [118,119]. In addition, Zika"/>
 <result pre="inhibited by azithromycin [120,121]. During the early phase of influenza" exact="virus infection," post="azithromycin has been found to block influenza virus endocytosis"/>
 <result pre="is a weak base that could inhibit endocytosis, thus limiting" exact="viral" post="entry and replication [122]. Secondly, azithromycin directly affects the"/>
 <result pre="replication [122]. Secondly, azithromycin directly affects the activity of bronchial" exact="epithelial" post="cells and decreases mucus production, thus improving lung function"/>
 <result pre="the stimulation of IFN genes, leading to a reduction of" exact="viral" post="replication [124]. Lastly and recently, azithromycin was shown to"/>
 <result pre="homologs enzyme to ACE expresses on the membrane of lung" exact="epithelial" post="cells, which is followed by virus-cell fusion and viral"/>
 <result pre="lung epithelial cells, which is followed by virus-cell fusion and" exact="viral" post="entry; see Figure 1, [125,126,127,128]. ACE-2 is a zinc"/>
 <result pre="(ANGI) after being cleaved by ACE. ANGII binds to angiotensin" exact="type 1" post="receptor (AT1R) and functionally results in blood pressure elevation."/>
 <result pre="degrading it into angiotensin-(1â€&quot;7), which binds to Mas receptors on" exact="blood vessels," post="thus resulting in a vasodilator effect [12]. Furthermore, ACE2"/>
 <result pre="negative regulator in the reninâ€&quot;aldosteroneâ€&quot;angiotensin system and opposes the deleterious" exact="cardiovascular" post="effects induced by that system [126,129]. ANGII plays an"/>
 <result pre="ANGII plays an important role in regulating ACE2. In the" exact="absence of" post="abnormally elevated levels of Ang II, complex formation between"/>
 <result pre="categories of antihypertensive treatment that are extensively used to treat" exact="hypertension" post="and other cardiovascular diseases. ACEi and ARB increase the"/>
 <result pre="treatment that are extensively used to treat hypertension and other" exact="cardiovascular" post="diseases. ACEi and ARB increase the expression of ACE2"/>
 <result pre="and ARB increase the expression of ACE2 on the lung" exact="epithelial" post="cell surface [126,129]. Therefore, it has been suggested that"/>
 <result pre="of SARS-CoV-2 spike glycoprotein to ACE2 and hence reduce SARS-CoV-2" exact="viral" post="entry [129]. Furthermore, Dijkman et al. suggested that viral"/>
 <result pre="SARS-CoV-2 viral entry [129]. Furthermore, Dijkman et al. suggested that" exact="viral" post="replication directly diminishes cellular ACE2 levels [130]. This may"/>
 <result pre="ARB via increasing the ACE2 levels and opposing the SARS-CoV-2" exact="infection" post="consequences. Losartan is an AT1R blocker that is widely"/>
 <result pre="AT1R blocker that is widely applied in the management of" exact="hypertension" post="and to slow down the nephropathy progression in patients"/>
 <result pre="in the management of hypertension and to slow down the" exact="nephropathy" post="progression in patients with diabetes mellitus. It is a"/>
 <result pre="and to slow down the nephropathy progression in patients with" exact="diabetes mellitus." post="It is a safe drug with infrequent adverse drug"/>
 <result pre="ACE2 (rhACE2; APN01, and GSK2586881) is safe in patients with" exact="acute" post="respiratory distress syndrome [134,135]. Treatment with rhACE2 rapidly abolishes"/>
 <result pre="(rhACE2; APN01, and GSK2586881) is safe in patients with acute" exact="respiratory" post="distress syndrome [134,135]. Treatment with rhACE2 rapidly abolishes the"/>
 <result pre="and GSK2586881) is safe in patients with acute respiratory distress" exact="syndrome" post="[134,135]. Treatment with rhACE2 rapidly abolishes the elevated levels"/>
 <result pre="small clinical trial of rhACE2 in patients with severe SARS-CoV-2" exact="infection" post="was recently initiated (NCT04287686). Logically, low cellular membrane ACE2"/>
 <result pre="on the lung cell surface, the higher the chance of" exact="viral" post="entry and the lower chance lung injury, due to"/>
 <result pre="surface, the higher the chance of viral entry and the" exact="lower" post="chance lung injury, due to minimal AT1R activation. This"/>
 <result pre="of ACE2 and, hence, ACEi/ARB or rhACE2, treatment in SARS-CoV-2" exact="infection" post="need more investigation. 6.2. Camostat In-vitro studies have shown"/>
 <result pre="at the cell surface [137]. TMPRSS2 activity is crucial for" exact="viral" post="spread and pathogenesis in an infected host [16,138], and"/>
 <result pre="mice, camostat was also found to prevent the development of" exact="pneumonia" post="and viral myocarditis [140]. Moreover, camostat mesylate has been"/>
 <result pre="was also found to prevent the development of pneumonia and" exact="viral" post="myocarditis [140]. Moreover, camostat mesylate has been found to"/>
 <result pre="also found to prevent the development of pneumonia and viral" exact="myocarditis" post="[140]. Moreover, camostat mesylate has been found to help"/>
 <result pre="has been found to help to slow down or inhibit" exact="chronic" post="pancreatitis in animal models and has been used for"/>
 <result pre="been found to help to slow down or inhibit chronic" exact="pancreatitis" post="in animal models and has been used for the"/>
 <result pre="animal models and has been used for the treatment of" exact="chronic" post="pancreatitis patients in Japan [141]. Therefore, camostat mesylate could"/>
 <result pre="models and has been used for the treatment of chronic" exact="pancreatitis" post="patients in Japan [141]. Therefore, camostat mesylate could also"/>
 <result pre="the papain-like protease domain of nsp3 from the Middle East" exact="respiratory" post="syndrome coronavirusJ. Virol.201488125111252710.1128/JVI.01294-1425142582 10.TsengY.-T.WangS.-M.HuangK.-J.LeeA.I.-R.ChiangC.-C.WangC.-T.Self-assembly of severe acute respiratory syndrome"/>
 <result pre="papain-like protease domain of nsp3 from the Middle East respiratory" exact="syndrome" post="coronavirusJ. Virol.201488125111252710.1128/JVI.01294-1425142582 10.TsengY.-T.WangS.-M.HuangK.-J.LeeA.I.-R.ChiangC.-C.WangC.-T.Self-assembly of severe acute respiratory syndrome coronavirus"/>
 <result pre="the Middle East respiratory syndrome coronavirusJ. Virol.201488125111252710.1128/JVI.01294-1425142582 10.TsengY.-T.WangS.-M.HuangK.-J.LeeA.I.-R.ChiangC.-C.WangC.-T.Self-assembly of severe" exact="acute" post="respiratory syndrome coronavirus membrane proteinJ. Biol. Chem.2010285128621287210.1074/jbc.M109.03027020154085 11.SiuY.L.TeohK.T.LoJ.ChanC.M.KienF.EscriouN.TsaoS.W.NichollsJ.M.AltmeyerR.PeirisJ.S.M.et al.The"/>
 <result pre="Middle East respiratory syndrome coronavirusJ. Virol.201488125111252710.1128/JVI.01294-1425142582 10.TsengY.-T.WangS.-M.HuangK.-J.LeeA.I.-R.ChiangC.-C.WangC.-T.Self-assembly of severe acute" exact="respiratory" post="syndrome coronavirus membrane proteinJ. Biol. Chem.2010285128621287210.1074/jbc.M109.03027020154085 11.SiuY.L.TeohK.T.LoJ.ChanC.M.KienF.EscriouN.TsaoS.W.NichollsJ.M.AltmeyerR.PeirisJ.S.M.et al.The M,"/>
 <result pre="East respiratory syndrome coronavirusJ. Virol.201488125111252710.1128/JVI.01294-1425142582 10.TsengY.-T.WangS.-M.HuangK.-J.LeeA.I.-R.ChiangC.-C.WangC.-T.Self-assembly of severe acute respiratory" exact="syndrome" post="coronavirus membrane proteinJ. Biol. Chem.2010285128621287210.1074/jbc.M109.03027020154085 11.SiuY.L.TeohK.T.LoJ.ChanC.M.KienF.EscriouN.TsaoS.W.NichollsJ.M.AltmeyerR.PeirisJ.S.M.et al.The M, E,"/>
 <result pre="al.The M, E, and N structural proteins of the severe" exact="acute" post="respiratory syndrome coronavirus are required for efficient assembly, trafficking,"/>
 <result pre="M, E, and N structural proteins of the severe acute" exact="respiratory" post="syndrome coronavirus are required for efficient assembly, trafficking, and"/>
 <result pre="E, and N structural proteins of the severe acute respiratory" exact="syndrome" post="coronavirus are required for efficient assembly, trafficking, and release"/>
 <result pre="proteomics reveal potential therapy targetsRes. Sq.202010.21203/rs.3.rs-17218/v1 15.LoM.K.FeldmannF.GaryJ.M.JordanR.BannisterR.CroninJ.PatelN.R.KlenaJ.D.NicholS.T.CihlarT.et al.Remdesivir (GS-5734) protects" exact="African" post="green monkeys from Nipah virus challengeSci. Transl. Med.201911eaau924210.1126/scitranslmed.aau924231142680 16.MadelainV.BaizeS.JacquotF.ReynardS.FizetA.BarronS.SolasC.LacarelleB.CarbonnelleC.MentrÃ©F.et"/>
 <result pre="green monkeys from Nipah virus challengeSci. Transl. Med.201911eaau924210.1126/scitranslmed.aau924231142680 16.MadelainV.BaizeS.JacquotF.ReynardS.FizetA.BarronS.SolasC.LacarelleB.CarbonnelleC.MentrÃ©F.et al.Ebola" exact="viral" post="dynamics in nonhuman primates provides insights into virus immuno-pathogenesis"/>
 <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirusJ. Biol. Chem.20202954772477910.1074/jbc.AC120.013056 19.De WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.ScottD.CihlarT.FeldmannH.Prophylactic and therapeutic remdesivir"/>
 <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirusJ. Biol. Chem.20202954772477910.1074/jbc.AC120.013056 19.De WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.ScottD.CihlarT.FeldmannH.Prophylactic and therapeutic remdesivir (GS-5734)"/>
 <result pre="23.ChanJ.F.-W.YaoY.YeungM.-L.DengW.BaoL.JiaL.LiF.XiaoC.GaoH.YuP.et al.Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmosetJ. Infect."/>
 <result pre="activityClin. Pharmacol. Ther.20108732232910.1038/clpt.2009.22820043009 30.FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc. Jpn. Acad. Ser. B20179344946310.2183/pjab.93.02728769016 31.BoothC.M.MatukasL.M.TomlinsonG.A.RachlisA.R.RoseD.B.DwoshH.A.WalmsleyS.L.MazzulliT.AvendanoM.DerkachP.et al.Clinical features"/>
 <result pre="in the greater Toronto areaJAMA20032892801280910.1001/jama.289.21.JOC3088512734147 32.LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.B.ToK.F.et al.A Major Outbreak of" exact="Severe" post="Acute Respiratory Syndrome in Hong KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352"/>
 <result pre="the greater Toronto areaJAMA20032892801280910.1001/jama.289.21.JOC3088512734147 32.LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.B.ToK.F.et al.A Major Outbreak of Severe" exact="Acute" post="Respiratory Syndrome in Hong KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 33.ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.et"/>
 <result pre="greater Toronto areaJAMA20032892801280910.1001/jama.289.21.JOC3088512734147 32.LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.B.ToK.F.et al.A Major Outbreak of Severe Acute" exact="Respiratory" post="Syndrome in Hong KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 33.ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.et al.Role"/>
 <result pre="Toronto areaJAMA20032892801280910.1001/jama.289.21.JOC3088512734147 32.LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.B.ToK.F.et al.A Major Outbreak of Severe Acute Respiratory" exact="Syndrome" post="in Hong KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 33.ChuC.M.ChengV.C.C.HungI.F.N.WongM.M.L.ChanK.H.ChanK.S.KaoR.Y.T.PoonL.L.M.WongC.L.P.GuanY.et al.Role of"/>
 <result pre="and interferon therapy in patients infected with the Middle East" exact="respiratory" post="syndrome coronavirus: An observational studyInt. J. Infect. Dis.201420424610.1016/j.ijid.2013.12.00324406736 35.OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin"/>
 <result pre="interferon therapy in patients infected with the Middle East respiratory" exact="syndrome" post="coronavirus: An observational studyInt. J. Infect. Dis.201420424610.1016/j.ijid.2013.12.00324406736 35.OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and"/>
 <result pre="Infect. Dis.201420424610.1016/j.ijid.2013.12.00324406736 35.OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East" exact="respiratory" post="syndrome coronavirus infection: A retrospective cohort studyLancet Infect. Dis.2014141090109510.1016/S1473-3099(14)70920-X25278221"/>
 <result pre="Dis.201420424610.1016/j.ijid.2013.12.00324406736 35.OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe Middle East respiratory" exact="syndrome" post="coronavirus infection: A retrospective cohort studyLancet Infect. Dis.2014141090109510.1016/S1473-3099(14)70920-X25278221 36.SpanakisN.TsiodrasS.HaagmansB.L.RajV.S.PontikisK.KoutsoukouA.KoulourisN.G.OsterhausA.D.M.E.KoopmansM.P.G.TsakrisA.Virological"/>
 <result pre="Dis.2014141090109510.1016/S1473-3099(14)70920-X25278221 36.SpanakisN.TsiodrasS.HaagmansB.L.RajV.S.PontikisK.KoutsoukouA.KoulourisN.G.OsterhausA.D.M.E.KoopmansM.P.G.TsakrisA.Virological and serological analysis of a recent Middle East" exact="respiratory" post="syndrome coronavirus infection case on a triple combination antiviral"/>
 <result pre="36.SpanakisN.TsiodrasS.HaagmansB.L.RajV.S.PontikisK.KoutsoukouA.KoulourisN.G.OsterhausA.D.M.E.KoopmansM.P.G.TsakrisA.Virological and serological analysis of a recent Middle East respiratory" exact="syndrome" post="coronavirus infection case on a triple combination antiviral regimenInt."/>
 <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt. J. Antimicrob."/>
 <result pre="J. Antimicrob. Agents20144452853210.1016/j.ijantimicag.2014.07.02625288266 37.BoriskinY.LenevaI.PecheurE.-I.PolyakS.Arbidol: A broad-spectrum antiviral compound that blocks" exact="viral" post="fusionCurr. Med. Chem.200815997100510.2174/09298670878404965818393857 38.HaviernikJ.Å tefÃ¡nikM.FojtÃ­kovÃ¡M.KaliS.TordoN.RudolfI.HubÃ¡lekZ.EyerL.RuzekD.Arbidol (Umifenovir): A broad-spectrum antiviral"/>
 <result pre="inflammatory responses: From mechanisms to potential therapeutic toolsVirol. Sin.202010.1007/s12250-020-00207-432125642 46.ChenI.-Y.MoriyamaM.ChangM.-F.IchinoheT.Severe" exact="acute" post="respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasomeFront."/>
 <result pre="responses: From mechanisms to potential therapeutic toolsVirol. Sin.202010.1007/s12250-020-00207-432125642 46.ChenI.-Y.MoriyamaM.ChangM.-F.IchinoheT.Severe acute" exact="respiratory" post="syndrome coronavirus viroporin 3a activates the NLRP3 inflammasomeFront. Microbiol.20191010.3389/fmicb.2019.00050"/>
 <result pre="From mechanisms to potential therapeutic toolsVirol. Sin.202010.1007/s12250-020-00207-432125642 46.ChenI.-Y.MoriyamaM.ChangM.-F.IchinoheT.Severe acute respiratory" exact="syndrome" post="coronavirus viroporin 3a activates the NLRP3 inflammasomeFront. Microbiol.20191010.3389/fmicb.2019.00050 47.SheridanC.Fast,"/>
 <result pre="to curb coronavirus pandemicNat. Biotechnol.202010.1038/d41587-020-00010-2 48.LiuL.WeiQ.LinQ.FangJ.WangH.KwokH.TangH.NishiuraK.PengJ.TanZ.et al.Antiâ€&quot;spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARS-CoV"/>
 <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARS-CoV infectionJCI Insight2019410.1172/jci.insight.123158 49.TsengC.-T.SbranaE.Iwata-YoshikawaN.NewmanP.C.GarronT.AtmarR.L.PetersC.J.CouchR.B.Immunization with SARS coronavirus vaccines leads"/>
 <result pre="SARS-CoV infectionJCI Insight2019410.1172/jci.insight.123158 49.TsengC.-T.SbranaE.Iwata-YoshikawaN.NewmanP.C.GarronT.AtmarR.L.PetersC.J.CouchR.B.Immunization with SARS coronavirus vaccines leads to" exact="pulmonary" post="immunopathology on challenge with the SARS virusPLoS ONE20127e3542110.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a3549222536382 50.BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.FunkhouserW.GralinskiL.ToturaA.HeiseM.et"/>
 <result pre="challenge with the SARS virusPLoS ONE20127e3542110.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a3549222536382 50.BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.FunkhouserW.GralinskiL.ToturaA.HeiseM.et al.A double-inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccine provides incomplete protection in mice"/>
 <result pre="with the SARS virusPLoS ONE20127e3542110.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a3549222536382 50.BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.FunkhouserW.GralinskiL.ToturaA.HeiseM.et al.A double-inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccine provides incomplete protection in mice and"/>
 <result pre="the SARS virusPLoS ONE20127e3542110.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a3549222536382 50.BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.FunkhouserW.GralinskiL.ToturaA.HeiseM.et al.A double-inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
 <result pre="50.BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.FunkhouserW.GralinskiL.ToturaA.HeiseM.et al.A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides" exact="incomplete" post="protection in mice and induces increased eosinophilic proinflammatory pulmonary"/>
 <result pre="coronavirus vaccine provides incomplete protection in mice and induces increased" exact="eosinophilic" post="proinflammatory pulmonary response upon challengeJ. Virol.201185122011221510.1128/JVI.06048-1121937658 51.ZhangL.ZhangF.YuW.HeT.YuJ.YiC.E.BaL.LiW.FarzanM.ChenZ.et al.Antibody responses"/>
 <result pre="provides incomplete protection in mice and induces increased eosinophilic proinflammatory" exact="pulmonary" post="response upon challengeJ. Virol.201185122011221510.1128/JVI.06048-1121937658 51.ZhangL.ZhangF.YuW.HeT.YuJ.YiC.E.BaL.LiW.FarzanM.ChenZ.et al.Antibody responses against SARS"/>
 <result pre="Virol.201185122011221510.1128/JVI.06048-1121937658 51.ZhangL.ZhangF.YuW.HeT.YuJ.YiC.E.BaL.LiW.FarzanM.ChenZ.et al.Antibody responses against SARS coronavirus are correlated with" exact="disease" post="outcome of infected individualsJ. Med. Virol.2006781810.1002/jmv.2049916299724 52.HaslwanterD.BlaasD.HeinzF.X.StiasnyK.A novel mechanism"/>
 <result pre="55.LauplandK.B.KirkpatrickA.W.DelaneyA.Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and" exact="septic shock" post="in critically ill adults: A systematic review and meta-analysisCrit."/>
 <result pre="of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on" exact="acute" post="respiratory distress syndrome mortality: An open-label studyLancet Respir. Med.201429810710.1016/S2213-2600(13)70259-524503265"/>
 <result pre="intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute" exact="respiratory" post="distress syndrome mortality: An open-label studyLancet Respir. Med.201429810710.1016/S2213-2600(13)70259-524503265 59.RanieriV.M.PettilÃ¤V.KarvonenM.K.JalkanenJ.NightingaleP.BrealeyD.ManceboJ.FerrerR.MercatA.PatronitiN.et"/>
 <result pre="(FP-1201) on lung CD73 expression and on acute respiratory distress" exact="syndrome" post="mortality: An open-label studyLancet Respir. Med.201429810710.1016/S2213-2600(13)70259-524503265 59.RanieriV.M.PettilÃ¤V.KarvonenM.K.JalkanenJ.NightingaleP.BrealeyD.ManceboJ.FerrerR.MercatA.PatronitiN.et al.Effect of"/>
 <result pre="free from mechanical ventilation among patients with moderate to severe" exact="acute" post="respiratory distress syndromeJAMA202032372510.1001/jama.2019.22525 60.SiddiqiH.K.MehraM.R.COVID-19 illness in native and immunosuppressed"/>
 <result pre="from mechanical ventilation among patients with moderate to severe acute" exact="respiratory" post="distress syndromeJAMA202032372510.1001/jama.2019.22525 60.SiddiqiH.K.MehraM.R.COVID-19 illness in native and immunosuppressed states:"/>
 <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): The perspectives of clinical immunologists from ChinaClin."/>
 <result pre="clinical immunologists from ChinaClin. Immunol.202021410839310.1016/j.clim.2020.10839332222466 62.DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 63.CostantiniC.BelletM.M.ParianoM.RengaG.StincardiniC.GoldsteinA.L.GaraciE.RomaniL.A reappraisal of thymosin Alpha1"/>
 <result pre="2019 (COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 63.CostantiniC.BelletM.M.ParianoM.RengaG.StincardiniC.GoldsteinA.L.GaraciE.RomaniL.A reappraisal of thymosin Alpha1 in" exact="cancer" post="therapyFront. Oncol.2019987310.3389/fonc.2019.0087331555601 64.IwataS.TanakaY.Progress in understanding the safety and efficacy"/>
 <result pre="Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with" exact="rheumatoid arthritis" post="in two phase 3 studiesAnn. Rheum. Dis.201675A6210.1136/annrheumdis-2016-209124.147 68.KuboS.NakayamadaS.NakanoK.TanakaY.THU0203 baricitinib"/>
 <result pre="of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid" exact="arthritis" post="in two phase 3 studiesAnn. Rheum. Dis.201675A6210.1136/annrheumdis-2016-209124.147 68.KuboS.NakayamadaS.NakanoK.TanakaY.THU0203 baricitinib"/>
 <result pre="two phase 3 studiesAnn. Rheum. Dis.201675A6210.1136/annrheumdis-2016-209124.147 68.KuboS.NakayamadaS.NakanoK.TanakaY.THU0203 baricitinib targets the" exact="type I" post="IFN/STAT-medicated activities of human T cells and dendritic cellsAnn."/>
 <result pre="infected with MERS-CoVEmerg. Microbes Infect.201877710.1038/s41426-018-0063-829691378 85.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement activation contributes to severe" exact="acute" post="respiratory syndrome coronavirus pathogenesismBio20189e01753-1810.1128/mBio.01753-1830301856 86.WangK.ChenW.ZhouY.-S.LianJ.-Q.ZhangZ.DuP.GongL.ZhangY.CuiH.-Y.GengJ.-J.et al.SARS-CoV-2 invades host cells"/>
 <result pre="with MERS-CoVEmerg. Microbes Infect.201877710.1038/s41426-018-0063-829691378 85.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement activation contributes to severe acute" exact="respiratory" post="syndrome coronavirus pathogenesismBio20189e01753-1810.1128/mBio.01753-1830301856 86.WangK.ChenW.ZhouY.-S.LianJ.-Q.ZhangZ.DuP.GongL.ZhangY.CuiH.-Y.GengJ.-J.et al.SARS-CoV-2 invades host cells via"/>
 <result pre="MERS-CoVEmerg. Microbes Infect.201877710.1038/s41426-018-0063-829691378 85.GralinskiL.E.SheahanT.P.MorrisonT.E.MenacheryV.D.JensenK.LeistS.R.WhitmoreA.HeiseM.T.BaricR.S.Complement activation contributes to severe acute respiratory" exact="syndrome" post="coronavirus pathogenesismBio20189e01753-1810.1128/mBio.01753-1830301856 86.WangK.ChenW.ZhouY.-S.LianJ.-Q.ZhangZ.DuP.GongL.ZhangY.CuiH.-Y.GengJ.-J.et al.SARS-CoV-2 invades host cells via a"/>
 <result pre="of Clinical Trial for Actemra to Treat Hospitalized Patients with" exact="Severe" post="COVID-19 PneumoniaGenentech2332020Available online: https://www.gene.com/media/press-releases/14843/2020-03-23/genentech-announces-fda-approval-of-clin(accessed on 20 April 2020) 90.collab:"/>
 <result pre="20 April 2020) 90.collab: Commission TCNHChinese Clinical Guidance for COVID-19" exact="Pneumonia" post="Diagnosis and Treatment 2020Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/11/22/chinese-clinical-guidance-for-covid-19-pneumonia-diagnosis-and-treatment(accessed on 20 April"/>
 <result pre="on 20 April 2020) 91.LiuA.Roche Launches Clinical Trial of COVID-19" exact="Pneumonia" post="Hopeful Actemra after Backing from ChinaFiercePharma1932020Available online: https://www.fiercepharma.com/pharma/roche-launches-clinical-trial-covid-19-pneumonia-hopeful-actemra-after-backing-from-china(accessed on"/>
 <result pre="of Hepatotoxicity2019Available online: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69991a-eng.php(accessed on 20 April 2020) 93.CantiniF.NanniniC.NiccoliL.PetroneL.IppolitoG.GolettiD.Risk of" exact="tuberculosis" post="reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and"/>
 <result pre="20 April 2020) 93.CantiniF.NanniniC.NiccoliL.PetroneL.IppolitoG.GolettiD.Risk of tuberculosis reactivation in patients with" exact="rheumatoid arthritis," post="ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologicsMediators Inflamm.20172017890983410.1155/2017/890983428659665"/>
 <result pre="2020) 93.CantiniF.NanniniC.NiccoliL.PetroneL.IppolitoG.GolettiD.Risk of tuberculosis reactivation in patients with rheumatoid arthritis," exact="ankylosing spondylitis," post="and psoriatic arthritis receiving non-anti-TNF-targeted biologicsMediators Inflamm.20172017890983410.1155/2017/890983428659665 94.McCartyD.RobinsonA.Efficacy and"/>
 <result pre="tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and" exact="psoriatic arthritis" post="receiving non-anti-TNF-targeted biologicsMediators Inflamm.20172017890983410.1155/2017/890983428659665 94.McCartyD.RobinsonA.Efficacy and safety of sarilumab"/>
 <result pre="reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic" exact="arthritis" post="receiving non-anti-TNF-targeted biologicsMediators Inflamm.20172017890983410.1155/2017/890983428659665 94.McCartyD.RobinsonA.Efficacy and safety of sarilumab"/>
 <result pre="Adv. Musculoskelet. Dis.201810616710.1177/1759720X1775203729492111 95.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.202010.1016/S2213-2600(20)30076-X 96.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, Evaluation and"/>
 <result pre="Musculoskelet. Dis.201810616710.1177/1759720X1775203729492111 95.XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.LiuS.ZhaoP.LiuH.ZhuL.et al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.202010.1016/S2213-2600(20)30076-X 96.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.Features, Evaluation and Treatment"/>
 <result pre="April 2020) 97.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.XuZ.ShiL.WangY.ZhangJ.HuangL.et al.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet202039556557432007145 98.TotzeckM.MincuR.I.RassafT.Cardiovascular adverse events in patients with cancer"/>
 <result pre="2020) 97.CascellaM.RajnikM.CuomoA.DulebohnS.C.Di NapoliR.XuZ.ShiL.WangY.ZhangJ.HuangL.et al.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet202039556557432007145 98.TotzeckM.MincuR.I.RassafT.Cardiovascular adverse events in patients with cancer treated"/>
 <result pre="2019-nCoV acute respiratory diseaseLancet202039556557432007145 98.TotzeckM.MincuR.I.RassafT.Cardiovascular adverse events in patients with" exact="cancer" post="treated with bevacizumab: A meta-analysis of more than 20,000"/>
 <result pre="with bevacizumab: A meta-analysis of more than 20,000 patientsJ. Am." exact="Heart" post="Assoc.2017610.1161/JAHA.117.006278 99.CohenJ.A.ChunJ.Mechanisms of fingolimodâ€™s efficacy and adverse effects in"/>
 <result pre="efficacy and adverse effects in multiple sclerosisAnn. Neurol.20116975977710.1002/ana.2242621520239 100.CoppesO.J.M.GutierrezI.RederA.T.KsiazekS.BernardJ.Severe early" exact="bilateral" post="macular edema following fingolimod therapyMult. Scler. Relat. Disord.2013225625810.1016/j.msard.2012.11.00425877733 101.LeeS.J.SilvermanE.BargmanJ.M.The"/>
 <result pre="role of antimalarial agents in the treatment of SLE and" exact="lupus" post="nephritisNat. Rev. Nephrol.2011771872910.1038/nrneph.2011.15022009248 102.TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition of human immunodeficiency virus infectivity"/>
 <result pre="of SLE and lupus nephritisNat. Rev. Nephrol.2011771872910.1038/nrneph.2011.15022009248 102.TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition of human" exact="immunodeficiency" post="virus infectivity by chloroquineAIDS Res. Hum. Retroviruses1990648148910.1089/aid.1990.6.4811692728 103.OoiE.E.ChewJ.S.LohJ.P.ChuaR.C.In vitro"/>
 <result pre="virus replication by chloroquineVirol. J.200633910.1186/1743-422X-3-3916729896 104.FariasK.J.MachadoP.R.Da FonsecaB.A.Chloroquine inhibits dengue virus" exact="type 2" post="replication in Vero cells but not in C6/36 cellsScientificWorldJournal2013201328273410.1155/2013/28273423431254"/>
 <result pre="C6/36 cellsScientificWorldJournal2013201328273410.1155/2013/28273423431254 105.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an endocytosis blocking agent, inhibits zika" exact="virus infection" post="in different cell modelsViruses2016832210.3390/v8120322 106.JangC.H.ChoiJ.H.ByunM.S.JueD.M.Chloroquine inhibits production of TNF-alpha,"/>
 <result pre="cellsScientificWorldJournal2013201328273410.1155/2013/28273423431254 105.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an endocytosis blocking agent, inhibits zika virus" exact="infection" post="in different cell modelsViruses2016832210.3390/v8120322 106.JangC.H.ChoiJ.H.ByunM.S.JueD.M.Chloroquine inhibits production of TNF-alpha,"/>
 <result pre="lipopolysaccharide-stimulated human monocytes/macrophages by different modesRheumatology20064570371010.1093/rheumatology/kei28216418198 107.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: An old drug against todayâ€™s diseases?Lancet Infect. Dis2003372272710.1016/S1473-3099(03)00806-514592603"/>
 <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis. Off. Publ."/>
 <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis. Off. Publ. Infect."/>
 <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis. Off. Publ. Infect. Dis."/>
 <result pre="treatment of novel coronavirus pneumoniaChin. J. Tuberc. Respir. Dis.202043185188 110.collab:" exact="American" post="College of CardiologyVentricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment"/>
 <result pre="pneumoniaChin. J. Tuberc. Respir. Dis.202043185188 110.collab: American College of CardiologyVentricular" exact="Arrhythmia" post="Risk Due to Hydroxychloroquine-Azithromycin Treatment for COVID-192020Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19(accessed"/>
 <result pre="inhibitor IvermectinAntivir. Res.20139930130610.1016/j.antiviral.2013.06.00223769930 115.KosynaF.K.NagelM.KluxenL.KraushaarK.DeppingR.The importin alpha/beta-specific inhibitor Ivermectin affects HIF-dependent" exact="hypoxia" post="response pathwaysBiol. Chem.20153961357136710.1515/hsz-2015-017126351913 116.WagstaffK.M.SivakumaranH.HeatonS.M.HarrichD.JansD.A.Ivermectin is a specific inhibitor of"/>
 <result pre="the replication of SARS-CoV-2 in vitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 118.MinJ.Y.JangY.J.Macrolide therapy in" exact="respiratory" post="viral infectionsMediat. Inflamm.2012201264957010.1155/2012/649570 119.TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.ItoF.YamamotoT.KawachiS.AkagawaK.S.et al.Azithromycin, a 15-membered macrolide antibiotic,"/>
 <result pre="replication of SARS-CoV-2 in vitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 118.MinJ.Y.JangY.J.Macrolide therapy in respiratory" exact="viral" post="infectionsMediat. Inflamm.2012201264957010.1155/2012/649570 119.TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.ItoF.YamamotoT.KawachiS.AkagawaK.S.et al.Azithromycin, a 15-membered macrolide antibiotic, inhibits"/>
 <result pre="119.TranD.H.SugamataR.HiroseT.SuzukiS.NoguchiY.SugawaraA.ItoF.YamamotoT.KawachiS.AkagawaK.S.et al.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1) pdm09" exact="virus infection" post="by interfering with virus internalization processJ. Antibiot.20197275976810.1038/s41429-019-0204-x31300721 120.MadridP.B.PanchalR.G.WarrenT.K.ShurtleffA.C.EndsleyA.N.GreenC.E.KolokoltsovA.DaveyR.MangerI.D.GilfillanL.et al.Evaluation"/>
 <result pre="al.Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1) pdm09 virus" exact="infection" post="by interfering with virus internalization processJ. Antibiot.20197275976810.1038/s41429-019-0204-x31300721 120.MadridP.B.PanchalR.G.WarrenT.K.ShurtleffA.C.EndsleyA.N.GreenC.E.KolokoltsovA.DaveyR.MangerI.D.GilfillanL.et al.Evaluation"/>
 <result pre="in J774 macrophagesExp. Cell Res.20022818610010.1006/excr.2002.561312441132 123.CramerC.L.PattersonA.AlchakakiA.SoubaniA.O.Immunomodulatory indications of azithromycin in" exact="respiratory" post="disease: A concise review for the clinicianPostgrad. Med.201712949349910.1080/00325481.2017.128567728116959 124.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et"/>
 <result pre="review for the clinicianPostgrad. Med.201712949349910.1080/00325481.2017.128567728116959 124.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et al.Azithromycin protects against zika" exact="virus infection" post="by upregulating virus-induced type I and III interferon responsesAntimicrob."/>
 <result pre="for the clinicianPostgrad. Med.201712949349910.1080/00325481.2017.128567728116959 124.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et al.Azithromycin protects against zika virus" exact="infection" post="by upregulating virus-induced type I and III interferon responsesAntimicrob."/>
 <result pre="124.LiC.ZuS.DengY.-Q.LiD.ParvatiyarK.QuanquinN.ShangJ.SunN.SuJ.LiuZ.et al.Azithromycin protects against zika virus infection by upregulating virus-induced" exact="type I" post="and III interferon responsesAntimicrob. Agents Chemother.20196310.1128/AAC.00394-19 125.SandeepS.McGregorK.Energetics based modeling"/>
 <result pre="with SARSEur. J. Clin. Investig.20093961862510.1111/j.1365-2362.2009.02153.x19453650 128.ChenL.LiX.ChenM.FengY.XiongC.The ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
 <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc. Res.20201161097110010.1093/cvr/cvaa07832227090 129.DeshotelsM.R.XiaH.SriramulaS.LazartiguesE.FilipeanuC.M.Angiotensin II"/>
 <result pre="infected with SARS-CoV-2Cardiovasc. Res.20201161097110010.1093/cvr/cvaa07832227090 129.DeshotelsM.R.XiaH.SriramulaS.LazartiguesE.FilipeanuC.M.Angiotensin II mediates angiotensin converting enzyme" exact="type 2" post="internalization and degradation through an angiotensin II type I"/>
 <result pre="enzyme type 2 internalization and degradation through an angiotensin II" exact="type I" post="receptorâ€&quot;dependent mechanismHypertension2014641368137510.1161/HYPERTENSIONAHA.114.0374325225202 130.HammingI.CooperM.HaagmansB.HooperN.KorstanjeR.OsterhausA.TimensW.TurnerA.NavisG.Van GoorH.The emerging role of ACE2 in"/>
 <result pre="safety in essential hypertensionPharmacol. Ther.19977418119410.1016/S0163-7258(97)82002-59336021 133.YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.et al.Cardiovascular complications of severe" exact="acute" post="respiratory syndromePostgr. Med. J.20068214014410.1136/pgmj.2005.037515 134.HaschkeM.SchusterM.PoglitschM.LoibnerH.SalzbergM.BruggisserM.PenningerJ.KrahenbuhlS.Pharmacokinetics and pharmacodynamics of recombinant"/>
 <result pre="in essential hypertensionPharmacol. Ther.19977418119410.1016/S0163-7258(97)82002-59336021 133.YuC.M.WongR.S.WuE.B.KongS.L.WongJ.YipG.W.SooY.O.ChiuM.L.ChanY.S.HuiD.et al.Cardiovascular complications of severe acute" exact="respiratory" post="syndromePostgr. Med. J.20068214014410.1136/pgmj.2005.037515 134.HaschkeM.SchusterM.PoglitschM.LoibnerH.SalzbergM.BruggisserM.PenningerJ.KrahenbuhlS.Pharmacokinetics and pharmacodynamics of recombinant human"/>
 <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute" post="respiratory distress syndromeCrit. Care20172123410.1186/s13054-017-1823-x28877748 136.ZhouY.VedanthamP.LuK.AgudeloJ.CarrionR.Jr.NunneleyJ.W.BarnardD.PohlmannS.McKerrowJ.H.RensloA.R.et al.Protease inhibitors targeting coronavirus"/>
 <result pre="clinical trial of recombinant human angiotensin-converting enzyme 2 in acute" exact="respiratory" post="distress syndromeCrit. Care20172123410.1186/s13054-017-1823-x28877748 136.ZhouY.VedanthamP.LuK.AgudeloJ.CarrionR.Jr.NunneleyJ.W.BarnardD.PohlmannS.McKerrowJ.H.RensloA.R.et al.Protease inhibitors targeting coronavirus and"/>
 <result pre="proven protease inhibitorCell2020181271280.e810.1016/j.cell.2020.02.05232142651 139.KawaseM.ShiratoK.Van der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
 <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 140.ZhirnovO.P.KlenkH.D.WrightP.F.Aprotinin and similar protease"/>
 <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 140.ZhirnovO.P.KlenkH.D.WrightP.F.Aprotinin and similar protease inhibitors"/>
 <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJ. Virol.2012866537654510.1128/JVI.00094-1222496216 140.ZhirnovO.P.KlenkH.D.WrightP.F.Aprotinin and similar protease inhibitors as"/>
 <result pre="effects of the protease inhibitor camostat on pancreatic fibrosis and" exact="atrophy" post="in CCK-1 receptor-deficient ratsPancreas200530546115632700 Figure 1 Virus entry into"/>
 <result pre="host cell. The attachment protein â€œ-spike glycoproteinâ€� of the severe" exact="acute" post="respiratory syndrome-2 (SARS-CoV-2) uses a cellular attachment factor (angiotensin-converting"/>
 <result pre="cell. The attachment protein â€œ-spike glycoproteinâ€� of the severe acute" exact="respiratory" post="syndrome-2 (SARS-CoV-2) uses a cellular attachment factor (angiotensin-converting enzyme"/>
 <result pre="the use of soluble recombinant human ACE2 (which should slow" exact="viral" post="entry into cells via competitive binding with SARS-CoV-2). The"/>
 <result pre="with SARS-CoV-2). The structure of SARS-CoV-2 is shown in the" exact="upper" post="right. Figure 2 Inflammatory responses triggered by SARS-CoV-2 infection."/>
 <result pre="of SARS-CoV-2 is shown in the upper right. Figure 2" exact="Inflammatory" post="responses triggered by SARS-CoV-2 infection. Two inflammatory pathways may"/>
 <result pre="by SARS-CoV-2 infection. Two inflammatory pathways may be distinguished. The" exact="primary" post="pathway occurs as an early response to viral infection"/>
 <result pre="distinguished. The primary pathway occurs as an early response to" exact="viral infection" post="before the development of neutralizing antibodies (NAb). The secondary"/>
 <result pre="The primary pathway occurs as an early response to viral" exact="infection" post="before the development of neutralizing antibodies (NAb). The secondary"/>
 <result pre="viral infection before the development of neutralizing antibodies (NAb). The" exact="secondary" post="pathway begins with the release of Nab, which signifies"/>
 <result pre="is mediated by the virus-NAb complex and may lead to" exact="acute" post="lung injury through several pathways including the release of"/>
 <result pre="acute lung injury through several pathways including the release of" exact="monocyte" post="chemoattractant protein-1 and interleukin-8 (IL-8) from macrophages. pharmaceuticals-13-00096-t001_Table 1Table"/>
 <result pre="interleukin-8 (IL-8) from macrophages. pharmaceuticals-13-00096-t001_Table 1Table 1 Pharmacology of coronavirus" exact="disease" post="(COVID-19) therapies under clinical trials. Drug Mechanism of Action"/>
 <result pre="Registered Clinical Trials in COVID-19 Specific Antiviral Agents Remdesivir Inhibits" exact="viral" post="RdRp Intravenous Elevated ALT/AST (reversible); nephrotoxicity Known hypersensitivity Non-significant"/>
 <result pre="in COVID-19 Specific Antiviral Agents Remdesivir Inhibits viral RdRp Intravenous" exact="Elevated" post="ALT/AST (reversible); nephrotoxicity Known hypersensitivity Non-significant https://clinicaltrials.gov/ct2/show/NCT04330690https://clinicaltrials.gov/ct2/show/NCT04365725https://clinicaltrials.gov/ct2/show/NCT04292899https://clinicaltrials.gov/ct2/show/NCT04292730https://clinicaltrials.gov/ct2/show/NCT04252664https://clinicaltrials.gov/ct2/show/NCT04257656https://clinicaltrials.gov/ct2/show/NCT04280705 Lopinavir/Ritonavir Inhibits"/>
 <result pre="Remdesivir Inhibits viral RdRp Intravenous Elevated ALT/AST (reversible); nephrotoxicity Known" exact="hypersensitivity" post="Non-significant https://clinicaltrials.gov/ct2/show/NCT04330690https://clinicaltrials.gov/ct2/show/NCT04365725https://clinicaltrials.gov/ct2/show/NCT04292899https://clinicaltrials.gov/ct2/show/NCT04292730https://clinicaltrials.gov/ct2/show/NCT04252664https://clinicaltrials.gov/ct2/show/NCT04257656https://clinicaltrials.gov/ct2/show/NCT04280705 Lopinavir/Ritonavir Inhibits viral 3-chymotrypsin-like protease Oral Gastrointestinal,"/>
 <result pre="Elevated ALT/AST (reversible); nephrotoxicity Known hypersensitivity Non-significant https://clinicaltrials.gov/ct2/show/NCT04330690https://clinicaltrials.gov/ct2/show/NCT04365725https://clinicaltrials.gov/ct2/show/NCT04292899https://clinicaltrials.gov/ct2/show/NCT04292730https://clinicaltrials.gov/ct2/show/NCT04252664https://clinicaltrials.gov/ct2/show/NCT04257656https://clinicaltrials.gov/ct2/show/NCT04280705 Lopinavir/Ritonavir Inhibits" exact="viral" post="3-chymotrypsin-like protease Oral Gastrointestinal, nausea, vomiting, and diarrhea. Pancreatitis,"/>
 <result pre="CYP2C19 inducer. P-glycoprotein substrate; and 1 inducer https://clinicaltrials.gov/ct2/show/NCT04376814https://clinicaltrials.gov/ct2/show/NCT04321174https://clinicaltrials.gov/ct2/show/NCT04307693https://clinicaltrials.gov/ct2/show/NCT04350684https://clinicaltrials.gov/ct2/show/NCT04346147https://clinicaltrials.gov/ct2/show/NCT04261907https://clinicaltrials.gov/ct2/show/NCT04276688https://clinicaltrials.gov/ct2/show/NCT04330690 Darunavir/Cobicistat Inhibits" exact="viral" post="3-chymotrypsin-like protease Oral Dizziness, sleep disturbances, and altered sensorium."/>
 <result pre="upset, headache, skin rash, asthenia, and redistribution of fat Known" exact="hypersensitivity" post="Cobistat: CYP3A and 2D6 inhibitor; p-glycoprotein and OATP1B1 inhibitor"/>
 <result pre="and 2D6 inhibitor; p-glycoprotein and OATP1B1 inhibitor https://clinicaltrials.gov/ct2/show/NCT04252274http://www.chictr.org.cn/showprojen.aspx?proj=48992 Favipiravir Inhibits" exact="viral" post="RdRp Oral Anemia, neutropenia, hyperuricemia, diarrhea, and elevated ALT/AST."/>
 <result pre="RdRp Oral Anemia, neutropenia, hyperuricemia, diarrhea, and elevated ALT/AST. Known" exact="hypersensitivity" post="CYP2C8 and aldehyde oxidase inhibitor https://clinicaltrials.gov/ct2/show/NCT04376814 Ribavirin Inhibits viral"/>
 <result pre="Known hypersensitivity CYP2C8 and aldehyde oxidase inhibitor https://clinicaltrials.gov/ct2/show/NCT04376814 Ribavirin Inhibits" exact="viral" post="RdRp Oral Flu-like symptoms, depression, suicide, insomnia, irritability, relapse"/>
 <result pre="symptoms, depression, suicide, insomnia, irritability, relapse of drug abuse/overdose, and" exact="anemia" post="Known hypersensitivity Non-significant https://clinicaltrials.gov/ct2/show/NCT04276688 Umifenovir (arbidol) Inhibits spike protein/ACE2"/>
 <result pre="suicide, insomnia, irritability, relapse of drug abuse/overdose, and anemia Known" exact="hypersensitivity" post="Non-significant https://clinicaltrials.gov/ct2/show/NCT04276688 Umifenovir (arbidol) Inhibits spike protein/ACE2 interaction Oral"/>
 <result pre="hypersensitivity Non-significant https://clinicaltrials.gov/ct2/show/NCT04276688 Umifenovir (arbidol) Inhibits spike protein/ACE2 interaction Oral" exact="Hypersensitivity" post="Allergic reaction, GIT upset, and elevated ALT/AST Non-significant https://clinicaltrials.gov/ct2/show/NCT04350684"/>
 <result pre="Non-significant https://clinicaltrials.gov/ct2/show/NCT04276688 Umifenovir (arbidol) Inhibits spike protein/ACE2 interaction Oral Hypersensitivity" exact="Allergic" post="reaction, GIT upset, and elevated ALT/AST Non-significant https://clinicaltrials.gov/ct2/show/NCT04350684 Oseltamivir"/>
 <result pre="Neuroaminidase inhibitor Oral Nausea, vomiting, psychiatric effects, and nephrotoxicity Known" exact="hypersensitivity" post="Non-significant https://clinicaltrials.gov/ct2/show/NCT04261270https://clinicaltrials.gov/ct2/show/NCT04303299http://www.chictr.org.cn/searchprojen.aspx?regno=ChiCTR2000029603&amp;amp;title=&amp;amp;officialname=&amp;amp;subjectid=&amp;amp;secondaryid=&amp;amp;applier=&amp;amp;studyleader=&amp;amp;ethicalcommitteesanction=&amp;amp;sponsor=&amp;amp;studyailment=&amp;amp;studyailmentcode=&amp;amp;studytype=0&amp;amp;studystage=0&amp;amp;studydesign=0&amp;amp;minstudyexecutetime=&amp;amp;maxstudyexecutetime=&amp;amp;recruitmentstatus=0&amp;amp;gender=0&amp;amp;agreetosign=&amp;amp;secsponsor=&amp;amp;regstatus=0&amp;amp;country=&amp;amp;province=&amp;amp;city=&amp;amp;institution=&amp;amp;institutionlevel=&amp;amp;measure=&amp;amp;intercode=&amp;amp;sourceofspends=&amp;amp;createyear=0&amp;amp;isuploadrf=&amp;amp;whetherpublic=&amp;amp;btngo=btn&amp;amp;verifycode=&amp;amp;page=1 Non-Specific Antiviral Agents Intravenous Immunoglobulins Boosts the"/>
 <result pre="or flushing; an increased risk of thrombosis, renal dysfunction, and" exact="acute" post="renal failure IgA deficiency and prior hypersensitivity reactions are"/>
 <result pre="flushing; an increased risk of thrombosis, renal dysfunction, and acute" exact="renal failure" post="IgA deficiency and prior hypersensitivity reactions are not contraindications."/>
 <result pre="increased risk of thrombosis, renal dysfunction, and acute renal failure" exact="IgA deficiency" post="and prior hypersensitivity reactions are not contraindications. Non-significant https://clinicaltrials.gov/ct2/show/NCT04350580https://clinicaltrials.gov/ct2/show/NCT04348877(antibody-rich"/>
 <result pre="risk of thrombosis, renal dysfunction, and acute renal failure IgA" exact="deficiency" post="and prior hypersensitivity reactions are not contraindications. Non-significant https://clinicaltrials.gov/ct2/show/NCT04350580https://clinicaltrials.gov/ct2/show/NCT04348877(antibody-rich"/>
 <result pre="renal dysfunction, and acute renal failure IgA deficiency and prior" exact="hypersensitivity" post="reactions are not contraindications. Non-significant https://clinicaltrials.gov/ct2/show/NCT04350580https://clinicaltrials.gov/ct2/show/NCT04348877(antibody-rich plasma) Interferons Boosts"/>
 <result pre="the antiviral immune response in the early phase of the" exact="disease" post="subcutaneous GIT upset, urinary urgency, leukopenia, lymphocytopenia, neutropenia, and"/>
 <result pre="headache, insomnia, asthenia, and flu-like symptoms Hypersensitivity, pregnancy, current severe" exact="depression" post="or suicidal ideation, and liver failure. Inhibits metabolism of"/>
 <result pre="symptoms Hypersensitivity, pregnancy, current severe depression or suicidal ideation, and" exact="liver failure." post="Inhibits metabolism of zidovudine https://clinicaltrials.gov/ct2/show/NCT04350684(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04276688(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04350671(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04343976(IFN-Î») Immuno-Modulatory Agents Baricitinib JAK-1"/>
 <result pre="increased serum, alanine, aminotransferase, and serum aspartate aminotransferase History of" exact="venous thromboembolism" post="active or latent tuberculosis infection, pregnancy and lactation serious"/>
 <result pre="serum aspartate aminotransferase History of venous thromboembolism active or latent" exact="tuberculosis" post="infection, pregnancy and lactation serious acute infections, solid-organ transplant"/>
 <result pre="thromboembolism active or latent tuberculosis infection, pregnancy and lactation serious" exact="acute" post="infections, solid-organ transplant recipient, ALT/AST &amp;gt; 5 Ã— upper"/>
 <result pre="serious acute infections, solid-organ transplant recipient, ALT/AST &amp;gt; 5 Ã—" exact="upper" post="limit of normal, absolute neutrophil count &amp;lt; 1 Ã—"/>
 <result pre="may exist https://clinicaltrials.gov/ct2/show/NCT04358614https://clinicaltrials.gov/ct2/show/NCT04340232https://clinicaltrials.gov/ct2/show/NCT04346147https://clinicaltrials.gov/ct2/show/NCT04320277https://clinicaltrials.gov/ct2/show/NCT04373044https://clinicaltrials.gov/ct2/show/NCT04321993https://clinicaltrials.gov/ct2/show/NCT04345289 Ruxolitinib JAK1 and JAK2 inhibitor Oral Uncontrolled" exact="HIV infection," post="active tuberculosis, chronic kidney disease requiring dialysis, ALT/AST &amp;gt;"/>
 <result pre="JAK1 and JAK2 inhibitor Oral Uncontrolled HIV infection, active tuberculosis," exact="chronic" post="kidney disease requiring dialysis, ALT/AST &amp;gt; 5 times the"/>
 <result pre="and JAK2 inhibitor Oral Uncontrolled HIV infection, active tuberculosis, chronic" exact="kidney disease" post="requiring dialysis, ALT/AST &amp;gt; 5 times the upper limit"/>
 <result pre="JAK2 inhibitor Oral Uncontrolled HIV infection, active tuberculosis, chronic kidney" exact="disease" post="requiring dialysis, ALT/AST &amp;gt; 5 times the upper limit"/>
 <result pre="chronic kidney disease requiring dialysis, ALT/AST &amp;gt; 5 times the" exact="upper" post="limit of normal, and pregnancy or lactation. Known or"/>
 <result pre="death 1 (PD-1) blocking antibody Intravenous Reactive skin capillary hyperplasia," exact="hypothyroidism" post="pneumonia, asthenia, leukopenia, and neutropenia Pregnancy or lactation; known"/>
 <result pre="Intravenous Reactive skin capillary hyperplasia, hypothyroidism pneumonia, asthenia, leukopenia, and" exact="neutropenia" post="Pregnancy or lactation; known or expected to have allergic"/>
 <result pre="Reactive skin capillary hyperplasia, hypothyroidism pneumonia, asthenia, leukopenia, and neutropenia" exact="Pregnancy" post="or lactation; known or expected to have allergic reactions"/>
 <result pre="known or expected to have allergic reactions to the drug;" exact="autoimmune diseases;" post="history of organ, bone marrow, or hematopoietic stem cell"/>
 <result pre="hematopoietic stem cell transplantation; and received radiotherapy and chemotherapy for" exact="malignant" post="tumor within six months N/A https://clinicaltrials.gov/ct2/show/NCT04268537 Eculizumab Complement Inhibitor"/>
 <result pre="stem cell transplantation; and received radiotherapy and chemotherapy for malignant" exact="tumor" post="within six months N/A https://clinicaltrials.gov/ct2/show/NCT04268537 Eculizumab Complement Inhibitor Intravenous"/>
 <result pre="Eculizumab Complement Inhibitor Intravenous Increases the risk of meningococcal infections," exact="paroxysmal nocturnal hemoglobinuria" post="hemolytic uremic syndrome, and generalized asthenia Pregnancy or lactation,"/>
 <result pre="Complement Inhibitor Intravenous Increases the risk of meningococcal infections, paroxysmal" exact="nocturnal" post="hemoglobinuria hemolytic uremic syndrome, and generalized asthenia Pregnancy or"/>
 <result pre="Inhibitor Intravenous Increases the risk of meningococcal infections, paroxysmal nocturnal" exact="hemoglobinuria" post="hemolytic uremic syndrome, and generalized asthenia Pregnancy or lactation,"/>
 <result pre="Intravenous Increases the risk of meningococcal infections, paroxysmal nocturnal hemoglobinuria" exact="hemolytic uremic syndrome," post="and generalized asthenia Pregnancy or lactation, history or unresolved,"/>
 <result pre="meningococcal infections, paroxysmal nocturnal hemoglobinuria hemolytic uremic syndrome, and generalized" exact="asthenia" post="Pregnancy or lactation, history or unresolved, Neisseria meningitis infection,"/>
 <result pre="infections, paroxysmal nocturnal hemoglobinuria hemolytic uremic syndrome, and generalized asthenia" exact="Pregnancy" post="or lactation, history or unresolved, Neisseria meningitis infection, ongoing"/>
 <result pre="and generalized asthenia Pregnancy or lactation, history or unresolved, Neisseria" exact="meningitis" post="infection, ongoing sepsis, and the presence or suspicion of"/>
 <result pre="sepsis, and the presence or suspicion of active and untreated" exact="systemic" post="bacterial infection allergy Minor drug interactions may exist https://clinicaltrials.gov/ct2/show/NCT04346797https://clinicaltrials.gov/ct2/show/NCT04355494https://clinicaltrials.gov/ct2/show/NCT04288713"/>
 <result pre="and the presence or suspicion of active and untreated systemic" exact="bacterial infection" post="allergy Minor drug interactions may exist https://clinicaltrials.gov/ct2/show/NCT04346797https://clinicaltrials.gov/ct2/show/NCT04355494https://clinicaltrials.gov/ct2/show/NCT04288713 Meplazumab Anti-CD147"/>
 <result pre="the presence or suspicion of active and untreated systemic bacterial" exact="infection" post="allergy Minor drug interactions may exist https://clinicaltrials.gov/ct2/show/NCT04346797https://clinicaltrials.gov/ct2/show/NCT04355494https://clinicaltrials.gov/ct2/show/NCT04288713 Meplazumab Anti-CD147"/>
 <result pre="presence or suspicion of active and untreated systemic bacterial infection" exact="allergy" post="Minor drug interactions may exist https://clinicaltrials.gov/ct2/show/NCT04346797https://clinicaltrials.gov/ct2/show/NCT04355494https://clinicaltrials.gov/ct2/show/NCT04288713 Meplazumab Anti-CD147 antibody"/>
 <result pre="with tocilizumab are at an increased risk for developing serious" exact="infections" post="that may lead to hospitalization or death. Most patients"/>
 <result pre="lead to hospitalization or death. Most patients who developed these" exact="infections" post="were taking concomitant immunosuppressants, such as methotrexate or corticosteroids."/>
 <result pre="disease-modifying antirheumatic drugs (DMARDs). https://clinicaltrials.gov/ct2/show/NCT04275245 Sarilumab Interleukin-6 Receptor Antagonist Subcutaneous" exact="Elevated" post="ALT/AST Known or expected to have allergic reactions to"/>
 <result pre="It may enhance the immunosuppressive effect of DMARDs. https://clinicaltrials.gov/ct2/show/NCT04359901https://clinicaltrials.gov/ct2/show/NCT04357808https://clinicaltrials.gov/ct2/show/NCT04315298https://clinicaltrials.gov/ct2/show/NCT04357860https://clinicaltrials.gov/ct2/show/NCT04327388https://clinicaltrials.gov/ct2/show/NCT04324073https://clinicaltrials.gov/ct2/show/NCT04345289https://clinicaltrials.gov/ct2/show/NCT04322773https://clinicaltrials.gov/ct2/show/NCT02735707 Bevacizumab" exact="Antibody" post="against the vascular endothelial growth factor (VEGF) Intravenous Some"/>
 <result pre="the immunosuppressive effect of DMARDs. https://clinicaltrials.gov/ct2/show/NCT04359901https://clinicaltrials.gov/ct2/show/NCT04357808https://clinicaltrials.gov/ct2/show/NCT04315298https://clinicaltrials.gov/ct2/show/NCT04357860https://clinicaltrials.gov/ct2/show/NCT04327388https://clinicaltrials.gov/ct2/show/NCT04324073https://clinicaltrials.gov/ct2/show/NCT04345289https://clinicaltrials.gov/ct2/show/NCT04322773https://clinicaltrials.gov/ct2/show/NCT02735707 Bevacizumab Antibody against the" exact="vascular" post="endothelial growth factor (VEGF) Intravenous Some studies only reported"/>
 <result pre="and elevated AST/ALT A baseline QTc interval â‰¥ 500 msec," exact="heart" post="block, CAD, pregnancy, and known hypersensitivity Ketoconazole increases the"/>
 <result pre="interval â‰¥ 500 msec, heart block, CAD, pregnancy, and known" exact="hypersensitivity" post="Ketoconazole increases the drug level; vaccination may be less"/>
 <result pre="Anti-Infective Agents Repurposed to Treat COVID-19 Chloroquine and hydroxychloroquine Inhibits" exact="viral" post="entry and endocytosis Oral QTc prolongation, hypoglycemia, neuropsychiatric effects,"/>
 <result pre="Oral QTc prolongation, hypoglycemia, neuropsychiatric effects, and retinopathy Asian patients" exact="Ocular" post="diseaseVisual disturbancePorphyriaPsoriasis AlcoholismHepatic diseaseGIT diseaseG6PD deficiencyMyopathyNeurological diseaseHypoglycemia AV blockBradycardiaCardiomyopathyCeliac"/>
 <result pre="Ocular diseaseVisual disturbancePorphyriaPsoriasis AlcoholismHepatic diseaseGIT diseaseG6PD deficiencyMyopathyNeurological diseaseHypoglycemia AV blockBradycardiaCardiomyopathyCeliac" exact="disease" post="Heart failureHIV infectionHyperparathyroidismHypocalcemiaHypokalemiaHypomagnesemiaHypothyroidismLong QT syndrome Arsenic trioxideMethotrexateAcetaminophenIron productsKaolinNiacinRifampinIsoniazidAntiarrhythmicAnti-depressantsVitamins and"/>
 <result pre="diseaseVisual disturbancePorphyriaPsoriasis AlcoholismHepatic diseaseGIT diseaseG6PD deficiencyMyopathyNeurological diseaseHypoglycemia AV blockBradycardiaCardiomyopathyCeliac disease" exact="Heart" post="failureHIV infectionHyperparathyroidismHypocalcemiaHypokalemiaHypomagnesemiaHypothyroidismLong QT syndrome Arsenic trioxideMethotrexateAcetaminophenIron productsKaolinNiacinRifampinIsoniazidAntiarrhythmicAnti-depressantsVitamins and herbal"/>
 <result pre="diseaseG6PD deficiencyMyopathyNeurological diseaseHypoglycemia AV blockBradycardiaCardiomyopathyCeliac disease Heart failureHIV infectionHyperparathyroidismHypocalcemiaHypokalemiaHypomagnesemiaHypothyroidismLong QT" exact="syndrome" post="Arsenic trioxideMethotrexateAcetaminophenIron productsKaolinNiacinRifampinIsoniazidAntiarrhythmicAnti-depressantsVitamins and herbal productsAntacidsInsulin and antidiabetic agentsCyclosporinampicillin"/>
 <result pre="antidiabetic agentsCyclosporinampicillin https://clinicaltrials.gov/ct2/show/NCT04362332https://clinicaltrials.gov/ct2/show/NCT04328493https://clinicaltrials.gov/ct2/show/NCT04333628https://clinicaltrials.gov/ct2/show/NCT04331600https://clinicaltrials.gov/ct2/show/NCT04303507https://clinicaltrials.gov/ct2/show/NCT04351191https://clinicaltrials.gov/ct2/show/NCT04323527https://clinicaltrials.gov/ct2/show/NCT04308668https://clinicaltrials.gov/ct2/show/NCT04376814https://clinicaltrials.gov/ct2/show/NCT04330690 Ivermectin Abdominal pain, hypotension, mild ECG changes," exact="peripheral" post="and facial edema, transient tachycardia, hyperthermia, insomnia, somnolence, vertigo,"/>
 <result pre="Abdominal pain, hypotension, mild ECG changes, peripheral and facial edema," exact="transient" post="tachycardia, hyperthermia, insomnia, somnolence, vertigo, pruritus, eosinophilia, leukopenia, elevated"/>
 <result pre="elevated ALT/AST, myalgia, blurred vision, and Mazzotti reaction (with onchocerciasis)" exact="Hypersensitivity" post="to ivermectin Warfarin https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019 Azithromycin Inhibits viral entry and"/>
 <result pre="reaction (with onchocerciasis) Hypersensitivity to ivermectin Warfarin https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019 Azithromycin Inhibits" exact="viral" post="entry and endocytosis Oral QTc prolongation, diarrhea, nausea, and"/>
 <result pre="and endocytosis Oral QTc prolongation, diarrhea, nausea, and abdominal pain" exact="Hypersensitivity" post="to azithromycin, erythromycin, and any macrolides or ketolidesHistory of"/>
 <result pre="cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycinLong QT" exact="syndrome" post="NelfinavirWarfarinDigoxinColchicinePhenytoin https://clinicaltrials.gov/ct2/show/NCT04359316https://clinicaltrials.gov/ct2/show/NCT04332107https://clinicaltrials.gov/ct2/show/NCT04336332https://clinicaltrials.gov/ct2/show/NCT04341727 Drugs Acting on Host Cell Receptors Angiotensin-converting"/>
 <result pre="Acting on Host Cell Receptors Angiotensin-converting enzyme inhibitors Increases ACE2" exact="epithelial" post="cell lung expression Oral CoughCreatinine increasedSyncopeHyperkalemiaHypotension DiarrheaChest pain Abdominal"/>
 <result pre="lung expression Oral CoughCreatinine increasedSyncopeHyperkalemiaHypotension DiarrheaChest pain Abdominal pain Rash" exact="Infection" post="AstheniaAngina pectorisDyspneaPruritusHeadache Dizziness Increased BUN and serum creatinine Hypersensitivity"/>
 <result pre="increasedSyncopeHyperkalemiaHypotension DiarrheaChest pain Abdominal pain Rash Infection AstheniaAngina pectorisDyspneaPruritusHeadache Dizziness" exact="Increased" post="BUN and serum creatinine Hypersensitivity to ACE inhibitorsHistory of"/>
 <result pre="Rash Infection AstheniaAngina pectorisDyspneaPruritusHeadache Dizziness Increased BUN and serum creatinine" exact="Hypersensitivity" post="to ACE inhibitorsHistory of ACE inhibitor-induced angioedema and hereditary"/>
 <result pre="and serum creatinine Hypersensitivity to ACE inhibitorsHistory of ACE inhibitor-induced" exact="angioedema" post="and hereditary or idiopathic angioedemaCoadministration of neprilysin inhibitors with"/>
 <result pre="creatinine Hypersensitivity to ACE inhibitorsHistory of ACE inhibitor-induced angioedema and" exact="hereditary" post="or idiopathic angioedemaCoadministration of neprilysin inhibitors with aliskiren in"/>
 <result pre="idiopathic angioedemaCoadministration of neprilysin inhibitors with aliskiren in patients with" exact="diabetes mellitus" post="or with renal impairment Salt substitutes with potassiumNon-steroidal anti-inflammatory"/>
 <result pre="captopril)Probenecid (only with captopril) https://clinicaltrials.gov/ct2/show/NCT04366050https://clinicaltrials.gov/ct2/show/NCT04355429https://clinicaltrials.gov/ct2/show/NCT04345406https://clinicaltrials.gov/ct2/show/NCT04374695 Angiotensin receptor blockers Increases ACE2" exact="epithelial" post="cell lung expression Oral DizzinessHeadacheHyperkalemia. Bilateral renal artery stenosis"/>
 <result pre="receptor blockers Increases ACE2 epithelial cell lung expression Oral DizzinessHeadacheHyperkalemia." exact="Bilateral" post="renal artery stenosis ACEiAliskiren https://clinicaltrials.gov/ct2/show/NCT04335123https://clinicaltrials.gov/ct2/show/NCT04311177https://clinicaltrials.gov/ct2/show/NCT04312009https://clinicaltrials.gov/ct2/show/NCT04343001 Camostat Inhibits TMPRSS2 and"/>
 <result pre="ACE2 epithelial cell lung expression Oral DizzinessHeadacheHyperkalemia. Bilateral renal artery" exact="stenosis" post="ACEiAliskiren https://clinicaltrials.gov/ct2/show/NCT04335123https://clinicaltrials.gov/ct2/show/NCT04311177https://clinicaltrials.gov/ct2/show/NCT04312009https://clinicaltrials.gov/ct2/show/NCT04343001 Camostat Inhibits TMPRSS2 and prevent viral-cell entry"/>
 <result pre="entry Oral Abnormal liver function tests,DiarrheaHyperkalemiaItchingJaundiceLow blood plateletsLiver disorder GIT" exact="discomfort" post="Pregnancy (teratogenic) None https://clinicaltrials.gov/ct2/show/NCT04321096https://clinicaltrials.gov/ct2/show/NCT04353284https://clinicaltrials.gov/ct2/show/NCT04338906https://clinicaltrials.gov/ct2/show/NCT04355052 Abbreviations: Abbreviations: ABCB: ATP Binding"/>
 <result pre="Oral Abnormal liver function tests,DiarrheaHyperkalemiaItchingJaundiceLow blood plateletsLiver disorder GIT discomfort" exact="Pregnancy" post="(teratogenic) None https://clinicaltrials.gov/ct2/show/NCT04321096https://clinicaltrials.gov/ct2/show/NCT04353284https://clinicaltrials.gov/ct2/show/NCT04338906https://clinicaltrials.gov/ct2/show/NCT04355052 Abbreviations: Abbreviations: ABCB: ATP Binding Cassette"/>
 <result pre="Abbreviations: Abbreviations: ABCB: ATP Binding Cassette Subfamily B Member/ Multidrug" exact="Resistance" post="Protein; ACEi: angiotensin converting enzyme inhibitor; ALT: alanine transaminase;"/>
 <result pre="inhibitor; ALT: alanine transaminase; AST: aspartate transaminase; AV: atrio-ventricular; BCRP/ABCG2:" exact="Breast" post="cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2"/>
 <result pre="ALT: alanine transaminase; AST: aspartate transaminase; AV: atrio-ventricular; BCRP/ABCG2: Breast" exact="cancer" post="resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2);"/>
 <result pre="resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2); CAD:" exact="coronary artery disease;" post="CD: cluster of differentiation; CYP: cytochrome P450; DMARDs: disease"/>
 <result pre="protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2); CAD: coronary" exact="artery disease;" post="CD: cluster of differentiation; CYP: cytochrome P450; DMARDs: disease"/>
 <result pre="artery disease; CD: cluster of differentiation; CYP: cytochrome P450; DMARDs:" exact="disease" post="modifying antirheumatic drugs; ECG: electrocardiography; G6PD: glucose 6-phosphate dehydrogenase;"/>
</results>
